Elanco Animal Health (NYSE:ELAN) Announces Earnings Results, Beats Estimates By $0.07 EPS

Elanco Animal Health (NYSE:ELAN) released its quarterly earnings data on Friday. The company reported $0.27 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.20 by $0.07, FiscalAI reports. The firm had revenue of $1.26 billion during the quarter, compared to analysts’ expectations of $1.21 billion. Elanco Animal Health had a positive return on equity of 8.13% and a negative net margin of 3.96%. Elanco Animal Health’s revenue was up 11.3% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.19 earnings per share. Elanco Animal Health updated its Q4 2026 guidance to 0.160-0.190 EPS and its FY 2026 guidance to 1.170-1.200 EPS.

Here are the key takeaways from Elanco Animal Health’s conference call:

• Elanco reported 11% revenue growth in Q3, or 9% organic constant currency, and exceeded its guidance for revenue, adjusted EBITDA and adjusted EPS. The company raised full-year 2026 guidance, including adjusted EPS to $1.17–$1.20.
• Innovation products powered growth: Q3 innovation revenue rose 40% to $328 million, led by Zenrelia and Credelio Quattro, with both reaching record U.S. market share in September. Elanco raised its 2026 innovation revenue target to $1.275 billion and expects Befrena to be a significant U.S. Pet Health growth driver in 2027.
• Adjusted gross margin expanded 300 basis points to 56.1%, while the company generated $362 million in year-to-date free cash flow and reduced net leverage to 2.9 times. Management said productivity initiatives and growing innovation sales support further margin improvement.
• Management expects Q4 organic growth to moderate to 4%–6%, and flagged 2027 offsets including Costco’s non-renewal, regional farm-animal cycles, persistent inflation and initially dilutive Befrena growth. Elanco nevertheless reiterated its 2027 growth algorithm and expects pet health to outperform farm animal.
• Executives described competition as generally responsible but noted targeted promotions and corporate-account offers in parts of the market. They said these tactics may shift sales timing, but maintained that they do not expect a material change to the trajectory of share gains.

Elanco Animal Health Trading Up 8.3%

ELAN traded up $1.97 on Friday, reaching $25.65. 11,505,379 shares of the company’s stock were exchanged, compared to its average volume of 4,744,676. The company’s 50 day moving average is $23.13 and its 200-day moving average is $23.82. The company has a market cap of $12.81 billion, a price-to-earnings ratio of -62.55, a PEG ratio of 2.14 and a beta of 1.73. Elanco Animal Health has a twelve month low of $19.40 and a twelve month high of $27.98. The company has a debt-to-equity ratio of 0.58, a quick ratio of 1.10 and a current ratio of 2.05.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently issued reports on the stock. KeyCorp reiterated an “overweight” rating on shares of Elanco Animal Health in a research report on Wednesday, September 30th. Morgan Stanley dropped their price objective on Elanco Animal Health from $26.00 to $25.00 and set an “equal weight” rating for the company in a research note on Thursday, October 29th. The Goldman Sachs Group started coverage on Elanco Animal Health in a report on Friday, October 16th. They set a “buy” rating and a $32.00 price objective for the company. UBS Group increased their price objective on shares of Elanco Animal Health from $31.00 to $33.00 and gave the company a “buy” rating in a research note on Thursday, August 6th. Finally, Jefferies Financial Group downgraded Elanco Animal Health from a “buy” rating to a “hold” rating and dropped their price target for the stock from $31.00 to $24.00 in a research report on Tuesday, October 20th. One investment analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $29.33.

Insider Buying and Selling at Elanco Animal Health

In other Elanco Animal Health news, Director Michael J. Harrington purchased 5,000 shares of the firm’s stock in a transaction that occurred on Wednesday, August 12th. The stock was purchased at an average cost of $21.82 per share, with a total value of $109,100.00. Following the transaction, the director owned 131,451 shares in the company, valued at approximately $2,868,260.82. This trade represents a 3.95% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Shiv O’Neill bought 3,998 shares of the firm’s stock in a transaction dated Tuesday, August 18th. The stock was bought at an average cost of $23.58 per share, with a total value of $94,272.84. Following the transaction, the insider directly owned 87,832 shares of the company’s stock, valued at approximately $2,071,078.56. This trade represents a 4.77% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. In the last three months, insiders bought 48,998 shares of company stock valued at $1,139,373. 1.14% of the stock is currently owned by corporate insiders.

Key Stories Impacting Elanco Animal Health

Here are the key news stories impacting Elanco Animal Health this week:

• Positive Sentiment: Third-quarter adjusted EPS was $0.27, ahead of the $0.20 consensus, while revenue rose 11% year over year to $1.265 billion, topping estimates. Elanco also reported 9% organic constant-currency growth and gross-margin expansion. Read More.
• Positive Sentiment: Elanco raised its 2026 adjusted EPS outlook to $1.17–$1.20, versus the $1.13 consensus, and revenue guidance to $5.155–$5.18 billion, above the $5.1 billion consensus. It also lifted its innovation revenue target and improved its year-end net-leverage target to about 2.9x adjusted EBITDA. Read More.
• Positive Sentiment: Company survey findings offered further demand support: 93% of pet owners surveyed said they maintained or increased pet spending in the prior three months despite cost pressures. Read More.
• Neutral Sentiment: Fourth-quarter adjusted EPS guidance of $0.16–$0.19 brackets the $0.18 consensus, while revenue guidance of $1.2 billion matches estimates. Elanco’s early 2027 outlook calls for growth broadly in line with its previously stated long-term targets, rather than a further acceleration. Read More.

Elanco Animal Health Company Profile

Elanco Animal Health Incorporated is a global animal health company that develops, manufactures and markets products for pets and food-producing animals. Its portfolio is designed to help prevent and treat disease, control parasites and support the health and productivity of animals.

The company’s products include vaccines, parasiticides, antibiotics, nutritional supplements and other prescription and over-the-counter therapies. Its companion animal offerings address conditions such as flea and tick infestations, internal parasites, osteoarthritis and dermatological disorders, while its farm animal products support the health of cattle, poultry, swine and aquaculture species.

Elanco serves customers in markets around the world through relationships with veterinarians, animal owners, livestock producers, retailers and distributors.